## Highlights of This Issue 1125

### REVIEW

1127  
**Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools**  
Olaf Merkel, Frank Hamacher, Eveline Sifft, Lukas Kenner, and Richard Greil  
for the European Research Initiative on Anaplastic Large Cell Lymphoma  

### THERAPEUTIC DISCOVERY

1137  
**Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells**  
Chunyu Zhang, Abdel G. Elkahloun, Hongling Liao, Shannon Delaney, Barbara Saber, Betsy Morrow, George C. Prendergast, M. Christine Hollander, Joell J. Gills, and Phillip A. Dennis  

1149  
**Silencing IL-13Rα2 Promotes Glioblastoma Cell Death via Endogenous Signaling**  
Linda C. Hsi, Suman Kundu, Juan Palomo, Bo Xu, Ryan Ficco, Michael A. Vogelbaum, and Martha K. Cathcart  

1161  
**Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy**  
Ashutosh Shrivastava, Paula M. Kuzontkoski, Jerome E. Groopman, and Anil Prasad  

### PRECLINICAL DEVELOPMENT

1173  
**Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents**  
Qingbei Zhang, Vytas Bindokas, Jikun Shen, Hanli Fan, Robert M. Hoffman, and H. Rosie Xing  

1185  
**Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation**  

1194  
**Hsp90 Inhibitor–Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage**  

1207  
**Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue**  
Veronica Novotny-Diermayr, Nina Sausgruber, Yung Kiang Loh, Mohammed Khalid Pasha, Ramesh Jayaraman, Hannes Hentze, Wei-Peng Yong, Boon-Cher Goh, Han-Chong Toh, Kantharaj Ethirajulu, Joy Zhu, and Jeanette Marjorie Wood  

1218  
**E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor**  

1229  
**Characterization of the Oncogenic Activity of the Novel TRIM59 Gene in Mouse Cancer Models**  
Fatma Valiyeva, Fei Jiang, Ahmed Elmaadawi, Madeleine Moussa, Siu-Pok Yee, Leda Raptis, Jonathan I. Izawa, Burton B. Yang, Norman M. Greenberg, Fen Wang, and Jim W. Xuan
| 1241 | Sorafenib Enhances the Antitumor Effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA Repair Proteins  
Arti Yadav, Bhavna Kumar, Theodoros N. Teknos, and Pawan Kumar |
| 1252 | Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance In Vitro and In Vivo  
Ryuta Yamazaki, Yukiko Nishiyama, Tomio Furuta, Hiroshi Hatano, Yoshiaki Igarashi, Naoyuki Asakawa, Hiroshi Kodaira, Hiroyuki Takahashi, Ritsuo Aiyama, Takeshi Matsuzaki, Nao Yagi, and Yoshikazu Sugimoto |
| 1264 | Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP9X and Mcl-1  
Chong Zhang, Tian-yu Cai, Hong Zhu, Liu-qing Yang, Hai Jiang, Xiao-wu Dong, Yong-zhou Hu, Neng-ming Lin, Qiao-jun He, and Bo Yang |
| 1276 | Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells  
Hong Zhou, John W. Marks, Walter N. Hittelman, Hideo Yagita, Lawrence H. Cheung, Michael G. Rosenblum, and Jeffrey A. Winkles |

### MOLECULAR MEDICINE IN PRACTICE

| 1289 | Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer  
Raquel De Souza, Payam Zahedi, Rose M. Badame, Christine Allen, and Micheline Fiquette-Miller |
| 1300 | Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity  
Siqing Fu, Aung Naing, Stacy L. Moulder, Kirk S. Culotta, David C. Madoff, Chaan S. Ng, Timothy L. Madden, Gerald S. Falchook, David S. Hong, and Razelle Kurzrock |

### ABOUT THE COVER

A novel TRIM family member TRIM59 has proto-oncogenic activity in a transgenic mouse prostate cancer modeling test. Restricted TRIM59 gene expression in the mouse prostate using a prostate tissue-specific gene (PSP94) revealed the full potential for tumorigenesis and developed poorly differentiated cancer of the prostate and comedocarcinoma, which had features of neurocarcinoma (small cell carcinoma) and central necrosis. The PSP94-TRIM59 mice coincided with the upregulation of genes specific to the Ras signaling pathway and bridging genes for SV40Tag-mediated oncogenesis. For details, see the article by Valiyeva and colleagues on page 1229.
Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/10/7

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.